ATE325872T1 - Verfahren und zusammensetzungen zur behandlung von krebs - Google Patents

Verfahren und zusammensetzungen zur behandlung von krebs

Info

Publication number
ATE325872T1
ATE325872T1 AT96942100T AT96942100T ATE325872T1 AT E325872 T1 ATE325872 T1 AT E325872T1 AT 96942100 T AT96942100 T AT 96942100T AT 96942100 T AT96942100 T AT 96942100T AT E325872 T1 ATE325872 T1 AT E325872T1
Authority
AT
Austria
Prior art keywords
methods
compositions
treating cancer
treatment
vector
Prior art date
Application number
AT96942100T
Other languages
English (en)
Inventor
Gary L Clayman
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE325872T1 publication Critical patent/ATE325872T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96942100T 1995-11-30 1996-11-27 Verfahren und zusammensetzungen zur behandlung von krebs ATE325872T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US781095P 1995-11-30 1995-11-30

Publications (1)

Publication Number Publication Date
ATE325872T1 true ATE325872T1 (de) 2006-06-15

Family

ID=21728237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942100T ATE325872T1 (de) 1995-11-30 1996-11-27 Verfahren und zusammensetzungen zur behandlung von krebs

Country Status (19)

Country Link
US (3) US20020077313A1 (de)
EP (1) EP0863984B1 (de)
JP (1) JP2000501394A (de)
KR (1) KR19990071795A (de)
CN (2) CN1308450C (de)
AT (1) ATE325872T1 (de)
AU (1) AU722042B2 (de)
CA (1) CA2238829A1 (de)
CZ (1) CZ296810B6 (de)
DE (1) DE69636120T2 (de)
DK (1) DK0863984T3 (de)
ES (1) ES2264145T3 (de)
HU (1) HUP9902068A3 (de)
NO (1) NO982481L (de)
NZ (1) NZ324168A (de)
PL (1) PL186018B1 (de)
RU (1) RU2174409C2 (de)
SK (1) SK70598A3 (de)
WO (1) WO1997020047A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4492826B2 (ja) * 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
RU2219553C2 (ru) * 2001-10-18 2003-12-20 Ростовский научно-исследовательский онкологический институт Способ определения эффективности аутогемохимиотерапии рака ректосигмоидного отдела прямой кишки и сигмовидной кишки, а также аутогемохимиотерапии в сочетании с свч-гипертермией рака прямой кишки
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20050032728A1 (en) * 2002-12-17 2005-02-10 Sidney Kimmel Cancer Center Tumor suppression through bicistronic co-expression of p53 and p14ARF
AU2003300401A1 (en) * 2002-12-27 2004-07-29 Introgen Therapeutics, Inc. p53 treatment of papillomavirus and carcinogen-transformed cells in hyperplastic lesions
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004217830B2 (en) * 2003-03-06 2008-01-24 Zhaohui Peng A recombinant constructed by a virus vector and a human tumor suppressor gene and its use
RU2234099C1 (ru) * 2003-03-18 2004-08-10 Российская медицинская академия последипломного образования Способ дифференциальной диагностики стадий канцерогенеза
RU2242936C1 (ru) * 2003-04-21 2004-12-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака легкого
JP5005355B2 (ja) * 2004-02-23 2012-08-22 ノバルティス アーゲー 細胞毒性因子と組み合わせたｍＴＯＲ阻害剤での処置のためのバイオマーカーとしてのｐ５３野生型
US20080293652A1 (en) * 2004-02-24 2008-11-27 Introgen Therapeutics, Inc. Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours
CN100333797C (zh) * 2005-01-26 2007-08-29 彭朝晖 重组腺病毒p53制品在肿瘤治疗中的新用途
RU2245551C1 (ru) * 2004-04-23 2005-01-27 Белохвостов Александр Сергеевич Способ диагностики онкологических заболеваний
RU2263494C1 (ru) * 2004-06-08 2005-11-10 ГУ НИИ глазных болезней РАМН Способ моделирования меланомы роговицы
RU2410098C2 (ru) * 2004-08-31 2011-01-27 Новартис Аг Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
EP1679065A1 (de) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
TWI441646B (zh) * 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
CA2595959A1 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics, Inc. Methods for treating renal cell carcinoma
KR20080002863A (ko) * 2005-05-06 2008-01-04 오르소소프트 인코포레이티드 오브젝트를 트래킹하는 ｒｆ 시스템
US20070231304A1 (en) * 2006-01-30 2007-10-04 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
RU2371202C2 (ru) * 2007-07-30 2009-10-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ радионуклидной диагностики рака молочной железы
BRPI0907637A8 (pt) 2008-01-25 2018-01-02 P53 Inc biomarcadores p53
US8314068B2 (en) * 2008-04-14 2012-11-20 University Hospitals Of Cleveland P2X7 inhibition of epithelial cancers and papillomas
EP2300023A2 (de) * 2008-05-16 2011-03-30 Genelux Corporation Mikroorganismen zur prävention und behandlung von neoplasien neben einer zelltherapie
KR101840618B1 (ko) 2008-12-04 2018-03-20 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
RU2384845C1 (ru) * 2008-12-18 2010-03-20 ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов ФМБА Способ диагностики онкологических заболеваний
KR101763093B1 (ko) * 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
RU2395234C1 (ru) * 2009-07-24 2010-07-27 Учреждение Российской Академии Наук Институт Молекулярной Биологии Им. В.А. Энгельгардта Ран (Имб Ран) ОПРЕДЕЛЕНИЕ СНИЖЕНИЯ УРОВНЯ мРНК ГЕНА ZG16 КАК СПОСОБ ДИАГНОСТИКИ РАКА ТОЛСТОЙ КИШКИ И НАБОР ДЛЯ ЕГО ОСУЩЕСТВЛЕНИЯ
CN103391784A (zh) 2010-10-15 2013-11-13 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
CN103370076A (zh) 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
AU2012348332B2 (en) * 2011-12-08 2017-06-29 Haifeng Chen Vectors harboring toxic genes, methods and uses therefor
US9081453B2 (en) 2012-01-12 2015-07-14 Synaptics Incorporated Single layer capacitive imaging sensors
KR102112373B1 (ko) * 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
EP2968551B1 (de) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusionsproteine und verfahren dafür
WO2014158965A1 (en) * 2013-03-27 2014-10-02 Ge Healthcare As Method and reagent for preparing a diagnostic composition
AU2014281826B2 (en) * 2013-06-18 2019-10-17 Board Of Regents, The University Of Texas System Treatment of brain cancer with oncolytic adenovirus
US9552089B2 (en) 2013-08-07 2017-01-24 Synaptics Incorporated Capacitive sensing using a matrix electrode pattern
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
CN104357408A (zh) * 2014-03-13 2015-02-18 哈尔滨博翱生物医药技术开发有限公司 一种重组新城疫病毒及其应用
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
EP3201234B1 (de) 2014-09-30 2018-11-07 Diadem S.r.l. Antikörper zur bindung eines linearen epitops von humanem p53 und diagnostische anwendungen davon
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9778713B2 (en) 2015-01-05 2017-10-03 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
CN205028263U (zh) 2015-09-07 2016-02-10 辛纳普蒂克斯公司 一种电容传感器
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400B (zh) 2015-12-31 2021-10-29 辛纳普蒂克斯公司 单层传感器图案和感测方法
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
RU2760993C1 (ru) * 2021-02-15 2021-12-02 Сергей Александрович Никитин Способ рентгеновской терапии рака легких

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4748022A (en) * 1985-03-25 1988-05-31 Busciglio John A Topical composition
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US5055400A (en) * 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
US5017524A (en) * 1989-02-13 1991-05-21 Iscar Ltd. Ceramic cutting tool
US5527676A (en) * 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
US6800617B1 (en) * 1989-03-29 2004-10-05 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US6677312B1 (en) * 1989-03-29 2004-01-13 The Johns Hopkins University Methods for restoring wild-type p53 gene function
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0575518A1 (de) * 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen fuer die selektive hemmung von genexpression
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
EP0784690B1 (de) * 1994-06-10 2006-08-16 Genvec, Inc. Adenoviren-vektor systeme und zelllinien

Also Published As

Publication number Publication date
DE69636120T2 (de) 2006-11-30
EP0863984B1 (de) 2006-05-10
PL186018B1 (pl) 2003-09-30
CN101028523A (zh) 2007-09-05
HUP9902068A3 (en) 2001-02-28
US20060035857A1 (en) 2006-02-16
EP0863984A1 (de) 1998-09-16
KR19990071795A (ko) 1999-09-27
US20020077313A1 (en) 2002-06-20
RU2174409C2 (ru) 2001-10-10
US20030166603A1 (en) 2003-09-04
NO982481L (no) 1998-07-29
JP2000501394A (ja) 2000-02-08
AU1126397A (en) 1997-06-19
NO982481D0 (no) 1998-05-29
HUP9902068A2 (hu) 1999-10-28
CA2238829A1 (en) 1997-06-05
PL327009A1 (en) 1998-11-09
NZ324168A (en) 2004-11-26
CZ165798A3 (cs) 1998-12-16
ES2264145T3 (es) 2006-12-16
CZ296810B6 (cs) 2006-06-14
SK70598A3 (en) 1999-04-13
CN1207771A (zh) 1999-02-10
WO1997020047A1 (en) 1997-06-05
DE69636120D1 (de) 2006-06-14
DK0863984T3 (da) 2006-08-28
AU722042B2 (en) 2000-07-20
CN1308450C (zh) 2007-04-04

Similar Documents

Publication Publication Date Title
ATE325872T1 (de) Verfahren und zusammensetzungen zur behandlung von krebs
BR9610522A (pt) Composição para lavagem do corpo e processo para o tratamento da pele
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE69737793D1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
ATE366121T1 (de) Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE59603216D1 (de) Esterquats und ihre Verwendung zur Herstellung von oberflächenaktiven Mitteln, insbesondere zur Haar- und Körperpflege
DK0623134T3 (da) Metalkomplekser af vandopløselige texaphyriner
DE69932183D1 (de) ANWENDUNG VON ZIELGERICHTETEM RADIUM 223 FüR PALLIATIVE UND THERAPEUTISCHE BEHANDLUNG VON KNOCHENKREBS
BR9610375A (pt) Extrato de células composição cosmética ou farmacêutica utilização de pelo menos um extrato de células e processo de tratamento cosmético
MX9502240A (es) Pigmento opticamente variable, composiciones que lo contienen y proceso para su produccion.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
MY164077A (en) Compositions and uses of et743 for treating cancer
AU5690196A (en) 1h-pyrrol-1-yl and 1h-indol-1-yl aryl sulphones, processes f or their preparation and use for the therapy of hiv-1 infect ions
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
BR9610835A (pt) Composição cosmética ou dermatológica e processo não terapêutico de tratamento de matérias queratínicas
BR9806171A (pt) Composição cosmética e/ou dermatológica e pronta para uso, processo para tintura e para tratamento das fibras de queratina e dispositivo ou 'kit' de tintura de multi-compartimento
BR9808221A (pt) Método de tratamento de tumor.
ATE257708T1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
ATE232390T1 (de) Osmotisches nicht-fermentiertes laxans zur behandlung und vorbeugung von kolorektalem krebs
BE893738A (fr) Compositions cosmetiques pour le traitement des cheveux et de la peau contenant des polymeres essentiellement constitues de motifs repetitifs du type beta-alanine
FI924475A7 (fi) Trinitrobentseenien tai karmiinihapon käyttö syövän ja virusperäisten sairauksien hoidossa
DE59008012D1 (de) Mittel zur Behandlung von Leder und Pelzen.
EP0907720A4 (de) Kombinierte radiotherapie und immuntherapie zur behandlung von krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0863984

Country of ref document: EP